Quantcast

Industry news that matters to you.  Learn more

Detection of Key Epigenetic Biomarkers

Epigenetics refers to the study of heritable changes in genome function that occur without a change in the primary DNA sequence of an organism. One such change is DNA methylation, most frequently characterized by an enzymatic modification at the fifth position of cytosine (5-mC), present abundantly in the context of CpG dinucleotides. The formation and maintenance of 5-mC is catalyzed by cellular DNA (cytosine-5) methyltransferases (DNMTs).

Thermo Fisher, Proteome Sciences Form Biomarker Alliance

Thermo Fisher Scientific today said that it will collaborate with Proteome Sciences to develop quantitative proteomic workflows for biomarker discovery and validation.

Novartis Pharmaceuticals Partners with Orasi Medical

Orasi Medical, today announced that it has entered an agreement with Novartis Pharmaceuticals Corporation (Novartis) to develop a novel central nervous system (CNS) biomarker.

Improvement in Prediction of Blood Clots in Cancer Patients

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.

Neurogenetic Pharmaceuticals Announces Studies Showing its Proprietary Compound Reduces Brain Plaques Associated with Alzheimer’s Disease

In the Sept 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer’s disease (AD) in a transgenic mouse model. The study further demonstrates that following chronic treatment with the gamma secretase modulator (GSM) compound from NGP, the mice were devoid of gastrointestinal side effects, an adverse finding commonly associated with gamma secretase inhibitors (GSIs).